Repeated porphyrin lipoprotein‐based photodynamic therapy controls distant disease in mouse mesothelioma via the abscopal effect
Open Access
- 3 August 2021
- journal article
- research article
- Published by Wiley in Nanophotonics
- Vol. 10 (12) , 3279-3294
Abstract
While photodynamic therapy (PDT) can induce acute inflammation in the irradiated tumor site, a sustained systemic, adaptive immune response is desirable, as it may control the growth of nonirradiated distant disease. Previously, we developed porphyrin lipoprotein (PLP), a ∼20 nm nanoparticle photosensitizer, and observed that it not only efficiently eradicated irradiated primary VX2 buccal carcinomas in rabbits, but also induced regression of nonirradiated metastases in a draining lymph node. We hypothesized that PLP‐mediated PDT can induce an abscopal effect and we sought to investigate the immune mechanism underlying such a response in a highly aggressive, dual subcutaneous AE17‐OVA+ mesothelioma model in C57BL/6 mice. Four cycles of PLP‐mediated PDT was sufficient to delay the growth of a distal, nonirradiated tumor four‐fold relative to controls. Serum cytokine analysis revealed high interleukin‐6 levels, showing a 30‐fold increase relative to phosphate‐buffered solution (PBS) treated mice. Flow cytometry revealed an increase in CD4+ T cells and effector memory CD8+ T cells in non‐irradiated tumors. Notably, PDT in combination with PD‐1 antibody therapy prolonged survival compared to monotherapy and PBS. PLP‐mediated PDT shows promise in generating a systemic immune response that can complement other treatments, improving prognoses for patients with metastatic cancers.Keywords
Funding Information
- Princess Margaret Cancer Foundation
- Natural Sciences and Engineering Research Council of Canada (Grant Number 386613)
This publication has 37 references indexed in Scilit:
- Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effectsWorld Journal of Immunology, 2014
- Hypericin-photodynamic therapy leads to interleukin-6 secretion by HepG2 cells and their apoptosis via recruitment of BH3 interacting-domain death agonist and caspasesCell Death & Disease, 2013
- Involvement of damage-associated molecular patterns in tumor response to photodynamic therapy: surface expression of calreticulin and high-mobility group box-1 releaseCancer Immunology, Immunotherapy, 2011
- Photodynamic Therapy of Tumors Can Lead to Development of Systemic Antigen-Specific Immune ResponsePLOS ONE, 2010
- Malignant mesotheliomaOrphanet Journal of Rare Diseases, 2008
- Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunityCancer Immunology, Immunotherapy, 2008
- Photodynamic Therapy Enhancement of Antitumor Immunity Is Regulated by NeutrophilsCancer Research, 2007
- CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cellsBritish Journal of Cancer, 2007
- Acute phase response-associated systemic neutrophil mobilization in mice bearing tumors treated by photodynamic therapyInternational Immunopharmacology, 2006
- Choice of Oxygen-Conserving Treatment Regimen Determines the Inflammatory Response and Outcome of Photodynamic Therapy of TumorsCancer Research, 2004